Insider Trading Alert - TWO, CCL And BMRN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 3, 2014, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $420.42 to $5,791,625.60.

Highlighted Stocks Traded by Insiders:

Two Harbors Investment (TWO) - FREE Research Report

Sandberg Rebecca B, who is Secretary and General Counsel at Two Harbors Investment, sold 4,582 shares at $10.44 on June 3, 2014. Following this transaction, the Secretary and General Counsel owned 75,306 shares meaning that the stake was reduced by 5.74% with the 4,582-share transaction.

Siering Thomas, who is CEO, President at Two Harbors Investment, sold 20,000 shares at $10.45 on June 3, 2014. Following this transaction, the CEO, President owned 835,341 shares meaning that the stake was reduced by 2.34% with the 20,000-share transaction.

Roth William, who is Vice President, CIO at Two Harbors Investment, sold 20,000 shares at $10.45 on June 3, 2014. Following this transaction, the Vice President, CIO owned 580,334 shares meaning that the stake was reduced by 3.33% with the 20,000-share transaction.

Farrell Brad, who is Vice Pres., CFO & Treasurer at Two Harbors Investment, sold 8,583 shares at $10.45 on June 3, 2014. Following this transaction, the Vice Pres., CFO & Treasurer owned 177,981 shares meaning that the stake was reduced by 4.6% with the 8,583-share transaction.

The shares most recently traded at $10.28, down $0.17, or 1.65% since the insider transaction. Historical insider transactions for Two Harbors Investment go as follows:

  • 24-Week # shares bought: 15,000

The average volume for Two Harbors Investment has been 3.5 million shares per day over the past 30 days. Two Harbors Investment has a market cap of $3.8 billion and is part of the financial sector and real estate industry. Shares are up 10.78% year-to-date as of the close of trading on Tuesday.

Two Harbors Investment Corp. operates as a real estate investment trust (REIT) that focuses on investing in, financing, and managing residential mortgage-backed securities (RMBS), residential mortgage loans, mortgage servicing rights, and other financial assets. The stock currently has a dividend yield of 9.99%. The company has a P/E ratio of 9.6. Currently, there are 10 analysts who rate Two Harbors Investment a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TWO - FREE

TheStreet Quant Ratings rates Two Harbors Investment as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Two Harbors Investment Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Carnival (CCL) - FREE Research Report

Ma 1994 B Shares Lp, who is See remarks at Carnival, sold 144,377 shares at $40.11 on June 3, 2014. Following this transaction, the See remarks owned 97.8 million shares meaning that the stake was reduced by 0.15% with the 144,377-share transaction.

The shares most recently traded at $40.14, up $0.03, or 0.06% since the insider transaction. Historical insider transactions for Carnival go as follows:

  • 4-Week # shares sold: 22,998
  • 12-Week # shares sold: 720,981
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 2.8 million

The average volume for Carnival has been 3.3 million shares per day over the past 30 days. Carnival has a market cap of $23.7 billion and is part of the services sector and leisure industry. Shares are down 0.02% year-to-date as of the close of trading on Tuesday.

Carnival Corporation operates as a cruise company worldwide. It operates in two segments, North America; and Europe, Australia, & Asia. The stock currently has a dividend yield of 2.5%. The company has a P/E ratio of 30.3. Currently, there are 4 analysts who rate Carnival a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CCL - FREE

TheStreet Quant Ratings rates Carnival as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full Carnival Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Ajer Jeffrey Robert, who is SVP, Chief Commercial Of at Biomarin Pharmaceutical, sold 377 shares at $57.83 on June 3, 2014. Following this transaction, the SVP, Chief Commercial Of owned 20,190 shares meaning that the stake was reduced by 1.83% with the 377-share transaction.

The shares most recently traded at $62.30, up $4.47, or 7.17% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 10,580
  • 12-Week # shares sold: 11,961
  • 24-Week # shares sold: 12,877

The average volume for Biomarin Pharmaceutical has been 1.6 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $8.5 billion and is part of the health care sector and drugs industry. Shares are down 12.47% year-to-date as of the close of trading on Tuesday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently, there are 10 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries